Gynuity Health Projects


Resources by Type

Activities Brief

Materials Development Activities Brief

Technical Assistance Activities Brief

Training and Education Activities Brief

Policy and Advocacy Activities Brief

Social Science Research Activities Brief

Bibliography/ References

List of Mifepristone Approvals

Clinical Guidelines

Misoprostol for Early Abortion

Medical Abortion Guidebook

Misoprostol for Incomplete Abortion and Miscarriage

Misoprostol for prevention of postpartum hemorrhage

Guidebook on Misoprostol for Treatment of Incomplete Abortion

Abortion With Self-Administered Misoprostol: A Guide For Women

Misoprostol for Treatment of Postpartum Hemorrhage

Mife plus miso or miso-alone for abortion induction in pregnancies 12-24 weeks’ LMP

Mife plus miso or miso-alone for treatment of intrauterine fetal death 12-24 weeks’ LMP

Fact Sheet

FAQs on Fatal Infection and Medical Abortion - Summary

Postpartum Hemorrhage: A Challenge for Safe Motherhood

Issue Brief on Hormonal Contraception and HIV

FAQ on Hormonal Contraception and HIV

FAQs on Fatal Infection and Medical Abortion - Technical Version


Women’s Health

Youth Issues in Reproductive Health

Breast Cancer

Child Health

Emergency Contraceptives

Family Planning

Female Genital Mutilation

Infectious Disease



Pregnancy, Delivery, and Post-Natal Care

Pregnancy Termination/Abortion

Reproductive Tract Cancers

FAQ on Misoprostol Detection in Blood

FAQs on the Use of Multi-level Pregnancy Tests for Medical Abortion


Misoprostol for Postpartum Hemorrhage: Questions and Answers for Policy Makers


Map of Mifepristone Approvals

Map of Misoprostol Approvals

Meeting Report

Misoprostol and Teratogenicity: Reviewing the Evidence

Route of Misoprostol Administration

Misoprostol: A New Addition to Post Abortion Care

Misoprostol for Women’s Health

Relationship of Hormonal Contraception to HIV

Improving Current Therapies and Exploring New Options in Abortifacient Technology

Misoprostol, Abortion, and the Law

ICMA Third International Conference

The Product Problem:  Pathways for Making Misoprostol Available for Postpartum Hemorrhage

News Summary

Misoprostol added to the WHO Model List of Essential Medicines for the Treatment of PPH


Outlook Newsletter on Hormonal Contraception and HIV

PAC in Action Newsletter: Special Issue on Misoprostol in the PAC Context


Self-Administration of Misoprostol for Prevention of Postpartum Hemorrhage (PPH)

Policy Brief

Abortion in the Middle East and North Africa

Program Brief

Preeclampsia Program Brief

Postpartum hemorrhage

Medical Abortion Program Brief

Infectious Disease Program Brief

Pregnancy Failure and Miscarriage Program Brief

Institutional brochure

Contraception Program Brief

Project Description

Postpartum hemorrhage: Moving from Research to Reality

Misoprostol for Incomplete Abortion in Guatemala

Regional Profile

Medical abortion work in Eastern Europe/Central Asia

Research Summary


Blood Loss After Vaginal Delivery

Misoprostol for the Treatment of Postpartum Hemorrhage: Findings from Clinical Research Trials

Fever after treatment of postpartum hemorrhage

Expanding Choice in Abortion Services in Armenia

Misoprostol for the Prevention of Postpartum Hemorrhage: Findings from Research in Pakistan

Secondary Prevention/Early Treatment of PPH

Postpartum Hemorrhage Prevention in Nepal: A Program Assessment

Improving Care at Delivery for Women with Preeclampsia

Intravenous Versus Intramuscular Oxytocin for the Prevention of PPH

Staff Publication

Mifepristone medical abortion in Albania

Regimens of misoprostol with mifepristone for early medical abortion

Early pregnancy termination

Clostridium sordellii infection in medical abortion

Misoprostol for uterine evacuation in induced abortion and pregnancy failure

Use of sequential serum hCG and sonography for medical abortion only when indicated

Are two doses of misoprostol after mifepristone for early abortion better than one?

Alternatives to mifepristone for early medical abortion

Mifepristone for late first trimester abortion

Can mifepristone medical abortion be simplified?

Methotrexate compared to misoprostol alone for early medical abortion

Assessment of pregnancy duration among termination of pregnancy clients in South Africa

Abortion is for women

The supreme court and the partial-birth abortion ban act of 2003

Reproductive intentions among HIV-positive women and men

Misoprostol for incomplete abortion in Mozambique

Perspectives on reproductive decision-making amongst HIV-infected individuals

Misoprostol for incomplete abortion in Tanzania

Misoprostol for incomplete abortion in Burkina Faso

Treatment of postpartum hemorrhage with misoprostol

Prevention of postpartum hemorrhage with misoprostol

Treatment of incomplete abortion and miscarriage with misoprostol

Misoprostol to treat missed abortion in the first trimester

Supervision for use of mifepristone medical abortion

Community-based kangaroo mother care to prevent neonatal and infant mortality

Integrating medical abortion into safe abortion services in South Africa

Comment on Misoprostol impairs female reproductive tract innate immunity against C. sordellii